Targets › PKMYT1
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2027.
Acts as a negative regulator of entry into mitosis (G2 to M transition) by phosphorylation of the CDK1 kinase specifically when CDK1 is complexed to cyclins. Mediates phosphorylation of CDK1 predominantly on 'Thr-14'. Also involved in Golgi fragmentation. (UniProt, Q99640)
Open in Phaseline: the race on PKMYT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Debiopharm International | Lunresertib PKMYT1 inhibitor | PKMYT1 | Phase 1 | Advanced Solid Tumor | Dec 2027 |
| University Health Network, Toronto | RP-6306 PKMYT1 kinase inhibitor | PKMYT1 | Phase 1 | Recurrent Ovarian Cancer | – |
Advanced Solid Tumor (1) Recurrent Ovarian Cancer (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.